UK approves Cytokinetics’ Myqorzo as NICE backs NHS use in obstructive HCM

30 July 2026

US cardiovascular biotech Cytokinetics (Nasdaq: CYTK) has gained UK marketing authorization for Myqorzo (aficamten), while the National Institute for Health and Care Excellence (NICE) has recommended the cardiac myosin inhibitor for National Health Service (NHS) use in England and Wales in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

The Medicines and Healthcare products Regulatory Agency authorized the drug on Wednesday for eligible adults with New York Heart Association class II or III symptomatic oHCM. NICE published final guidance the following day, recommending aficamten as an add-on to optimized standard care, including beta-blockers, non-dihydropyridine calcium-channel blockers or disopyramide, or as monotherapy when those treatments cannot be used.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK